Do analysts rate CUPR or AIXC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CUPR or AIXC?

Cuprina Holdings (Cayman) has higher revenue and earnings than Qualigen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $49.89K 106.51 -$3.63M N/A N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is CUPR or AIXC more profitable?

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cuprina Holdings (Cayman) N/A N/A N/A Qualigen Therapeutics N/A -771.52% -79.52%

Do analysts rate TVGN or CUPR?

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Cuprina Holdings (Cayman). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, TVGN or CUPR?

Cuprina Holdings (Cayman) has higher revenue and earnings than Tevogen Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Cuprina Holdings (Cayman) $49.89K 106.51 -$3.63M N/A N/A

Is TVGN or CUPR more profitable?

Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Cuprina Holdings (Cayman) N/A N/A N/A

Does the media favor TVGN or CUPR?

In the previous week, Tevogen Bio and Tevogen Bio both had 1 articles in the media. Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat Tevogen Bio's score of 0.67 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cuprina Holdings (Cayman) 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NEUP or CUPR?

Neuphoria Therapeutics has higher revenue and earnings than Cuprina Holdings (Cayman). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuphoria Therapeutics $15.65M 1.17 -$370K -$11.06 N/A Cuprina Holdings (Cayman) $49.89K 106.51 -$3.63M N/A N/A

Is NEUP or CUPR more profitable?

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Cuprina Holdings (Cayman) N/A N/A N/A

Does the media favor NEUP or CUPR?

In the previous week, Neuphoria Therapeutics had 2 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 1 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat Neuphoria Therapeutics' score of 0.09 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cuprina Holdings (Cayman) 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, NRSN or CUPR?

Cuprina Holdings (Cayman) has higher revenue and earnings than NeuroSense Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Cuprina Holdings (Cayman) $49.89K 106.51 -$3.63M N/A N/A

Is NRSN or CUPR more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Cuprina Holdings (Cayman) N/A N/A N/A

Does the media favor NRSN or CUPR?

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat NeuroSense Therapeutics' score of 0.49 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cuprina Holdings (Cayman) 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CUPR or KZIA?

Novogen has a consensus price target of $25.80, indicating a potential upside of 94.72%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than Cuprina Holdings (Cayman). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable valuation & earnings, CUPR or KZIA?

Cuprina Holdings (Cayman) has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $49.89K 106.51 -$3.63M N/A N/A Novogen $30K 728.75 -$13.41M N/A N/A

Is CUPR or KZIA more profitable?

Company Net Margins Return on Equity Return on Assets Cuprina Holdings (Cayman) N/A N/A N/A Novogen N/A N/A N/A

Cuprina Holdings (Cayman) (CUPR) Competitors

$5.77 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.74 -0.03 (-0.49%)

As of 07/2/2026 07:59 PM Eastern

Compare

CUPR vs. AIXC, TVGN, NEUP, NRSN, and KZIA

Should you buy Cuprina Holdings (Cayman) stock or one of its competitors? MarketBeat compares Cuprina Holdings (Cayman) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cuprina Holdings (Cayman) include Qualigen Therapeutics (AIXC), Tevogen Bio (TVGN), Neuphoria Therapeutics (NEUP), NeuroSense Therapeutics (NRSN), and Novogen (KZIA). These companies are all part of the "pharmaceutical products" industry.

How does Cuprina Holdings (Cayman) compare to Qualigen Therapeutics?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Cuprina Holdings (Cayman) has higher revenue and earnings than Qualigen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$49.89K	106.51	-$3.63M	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Cuprina Holdings (Cayman) and 0 mentions for Qualigen Therapeutics. Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat Qualigen Therapeutics' score of 0.00 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
Qualigen Therapeutics	Neutral

Cuprina Holdings (Cayman) has a beta of -1.1, suggesting that its share price is 210% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Summary

Cuprina Holdings (Cayman) beats Qualigen Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Tevogen Bio and Tevogen Bio both had 1 articles in the media. Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat Tevogen Bio's score of 0.67 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Cuprina Holdings (Cayman) has higher revenue and earnings than Tevogen Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Cuprina Holdings (Cayman)	$49.89K	106.51	-$3.63M	N/A	N/A

Tevogen Bio has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, suggesting that its stock price is 210% less volatile than the broader market.

Summary

Cuprina Holdings (Cayman) beats Tevogen Bio on 4 of the 7 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

15.9% of Neuphoria Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Neuphoria Therapeutics has higher revenue and earnings than Cuprina Holdings (Cayman).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.17	-$370K	-$11.06	N/A
Cuprina Holdings (Cayman)	$49.89K	106.51	-$3.63M	N/A	N/A

Neuphoria Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 521.30%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, indicating that its share price is 210% less volatile than the broader market.

In the previous week, Neuphoria Therapeutics had 2 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 1 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat Neuphoria Therapeutics' score of 0.09 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neuphoria Therapeutics beats Cuprina Holdings (Cayman) on 9 of the 13 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Cuprina Holdings (Cayman)	N/A	N/A	N/A

NeuroSense Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, indicating that its share price is 210% less volatile than the broader market.

1.0% of NeuroSense Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cuprina Holdings (Cayman) has higher revenue and earnings than NeuroSense Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Cuprina Holdings (Cayman)	$49.89K	106.51	-$3.63M	N/A	N/A

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat NeuroSense Therapeutics' score of 0.49 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroSense Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 1,100.56%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NeuroSense Therapeutics beats Cuprina Holdings (Cayman) on 8 of the 11 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Novogen?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Novogen (NASDAQ:KZIA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

30.9% of Novogen shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cuprina Holdings (Cayman) has a beta of -1.1, meaning that its share price is 210% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Cuprina Holdings (Cayman) has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$49.89K	106.51	-$3.63M	N/A	N/A
Novogen	$30K	728.75	-$13.41M	N/A	N/A

In the previous week, Cuprina Holdings (Cayman) and Cuprina Holdings (Cayman) both had 1 articles in the media. Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat Novogen's score of 1.00 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
Novogen	Positive

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Novogen	N/A	N/A	N/A

Novogen has a consensus price target of $25.80, indicating a potential upside of 94.72%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Novogen beats Cuprina Holdings (Cayman) on 7 of the 10 factors compared between the two stocks.

Get Cuprina Holdings (Cayman) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUPR vs. The Competition

Export

Metric	Cuprina Holdings (Cayman)	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$5.31M	$791.45M	$5.20B	$12.48B
Dividend Yield	N/A	4.84%	16.11%	6.52%
P/E Ratio	N/A	1.66	23.91	24.70
Price / Sales	106.51	127.11	216.83	99.49
Price / Cash	N/A	20.06	35.06	57.09
Price / Book	3.85	8.17	13.25	6.46
Net Income	-$3.63M	-$3.71M	$113.80M	$337.01M
7 Day Performance	8.26%	2.59%	0.93%	1.69%
1 Month Performance	137.45%	4.41%	1.08%	3.81%
1 Year Performance	N/A	49.43%	10.03%	23.90%

Cuprina Holdings (Cayman) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUPR Cuprina Holdings (Cayman)	0.6153 of 5 stars	$5.77 flat	N/A	N/A	$5.31M	$49.89K	N/A	14	Gap Up
AIXC Qualigen Therapeutics	0.4238 of 5 stars	$1.22 +3.4%	N/A	N/A	$23.88M	N/A	N/A	50	Positive News Gap Down
TVGN Tevogen Bio	1.9459 of 5 stars	$5.74 +1.4%	$100.00 +1,642.2%	-90.7%	$23.70M	N/A	N/A	3	Positive News
NEUP Neuphoria Therapeutics	3.4107 of 5 stars	$3.55 -18.8%	$21.00 +491.5%	-52.6%	$23.62M	$15.65M	N/A	N/A	News Coverage Short Interest Decrease High Trading Volume
NRSN NeuroSense Therapeutics	3.7838 of 5 stars	$0.72 +0.4%	$8.50 +1,075.7%	-62.9%	$23.44M	N/A	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUPR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cuprina Holdings (Cayman) (CUPR) Competitors

CUPR vs. AIXC, TVGN, NEUP, NRSN, and KZIA

How does Cuprina Holdings (Cayman) compare to Qualigen Therapeutics?

Summary

How does Cuprina Holdings (Cayman) compare to Tevogen Bio?

Summary

How does Cuprina Holdings (Cayman) compare to Neuphoria Therapeutics?

Summary

How does Cuprina Holdings (Cayman) compare to NeuroSense Therapeutics?

Summary

How does Cuprina Holdings (Cayman) compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUPR vs. The Competition

Cuprina Holdings (Cayman) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cuprina Holdings (Cayman) (CUPR) Competitors

CUPR vs. AIXC, TVGN, NEUP, NRSN, and KZIA

How does Cuprina Holdings (Cayman) compare to Qualigen Therapeutics?

Is CUPR or AIXC more profitable?

Which has preferable valuation and earnings, CUPR or AIXC?

Do analysts rate CUPR or AIXC?

Do insiders & institutionals hold more shares of CUPR or AIXC?

Does the media refer more to CUPR or AIXC?

Which has more risk & volatility, CUPR or AIXC?

Summary

How does Cuprina Holdings (Cayman) compare to Tevogen Bio?

Does the media favor TVGN or CUPR?

Do analysts rate TVGN or CUPR?

Is TVGN or CUPR more profitable?

Which has higher valuation & earnings, TVGN or CUPR?

Which has more volatility and risk, TVGN or CUPR?

Summary

How does Cuprina Holdings (Cayman) compare to Neuphoria Therapeutics?

Do institutionals & insiders hold more shares of NEUP or CUPR?

Is NEUP or CUPR more profitable?

Which has preferable earnings and valuation, NEUP or CUPR?

Do analysts rate NEUP or CUPR?

Which has more volatility and risk, NEUP or CUPR?

Does the media favor NEUP or CUPR?

Summary

How does Cuprina Holdings (Cayman) compare to NeuroSense Therapeutics?

Is NRSN or CUPR more profitable?

Which has more risk & volatility, NRSN or CUPR?

Do insiders & institutionals hold more shares of NRSN or CUPR?

Which has better valuation and earnings, NRSN or CUPR?

Does the media favor NRSN or CUPR?

Do analysts recommend NRSN or CUPR?

Summary

How does Cuprina Holdings (Cayman) compare to Novogen?

Do institutionals and insiders believe in CUPR or KZIA?

Which has more volatility & risk, CUPR or KZIA?

Which has preferable valuation & earnings, CUPR or KZIA?

Does the media prefer CUPR or KZIA?

Is CUPR or KZIA more profitable?

Do analysts recommend CUPR or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUPR vs. The Competition

Cuprina Holdings (Cayman) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools